Startup Juno raises $120m for 'unprecedented' immunotherapies

The size of Juno Therapeutics's Series A venture funding round is a bright neon sign illuminating the drug development industry's growing enthusiasm for immunotherapies that can train patients' immune systems to attack cancer cells.